Trends in mortality and the effects of the COVID-19 pandemic on mortality among adult patients with Staphylococcus aureus bacteremia, 20 US counties, 2005-2022

Clicks: 36
ID: 325840
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #61 of 326 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 326 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Trends in Staphylococcus aureus bacteremia (SAB) mortality rates in the United States, including the impact of COVID-19, have not been well described. Methods Active, laboratory- and population-based surveillance data from 20 counties (seven states) were used to examine annual, 30-day mortality rates among U.S. adult patients with methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA, respectively) bacteremia during 2005-2022. Medical records and state vital statistics data were linked to ascertain death. Multivariable survival analysis estimated the association between recent SARS-CoV-2 infection (a positive SARS-CoV-2 test ≤30 days before incident culture) and mortality among SAB cases, adjusting for demographics and other risk factors. Analyses were stratified by MRSA/MSSA and epidemiologic class (hospital-onset [HO], healthcare-associated community-onset [HACO], and community-associated [CA]). Results Overall, SAB mortality was 21%. Annual SAB mortality rates were generally stable pre-pandemic before increasing by 33% and 41% among HO MRSA and MSSA cases, respectively, and by 49% among CA MRSA cases, but not among HACO or MSSA CA cases, from 2019 through 2021. Among HO cases with recent SARS-CoV-2 infection, annual mortality rates were as high as 75%. Adjusted hazard ratios for recent SARS-CoV-2 infection ranged from 1.9 (95% confidence interval: 1.5-2.3) (HACO MRSA) to 3.0 (95% confidence interval: 2.4-3.7) (HO MSSA). Conclusions Recent SARS-CoV-2 infection was a significant risk factor for death among patients with SAB during 2020-2022. Strengthening infection prevention efforts in similar respiratory pandemics in the future could help prevent increases in SAB mortality rates.
Reference Key
openalex_W7203871006 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carly Adams, Holly M. Biggs, Kelly A. Jackson, Joelle Nadle, Susan Petit, Susan M. Ray, Ruth Lynfield, Carmen Bernu, Ghinwa Dumyati, Marissa Walsh, William Schaffner, H Keipp Talbot, Lee H. Harrison, Isaac See
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag524
URL
https://doi.org/10.1093/ofid/ofag524
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.